Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06261814 · ClinicalTrials.gov registry record · Phase 2

Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

A Phase 2 study of Liver Neoplasms, sponsored by john eisenbrey.

Recruiting
Registry status
Phase 2
Development phase
266
Enrollment target
1
Study location

NCT06261814 is a Phase 2 study of Liver Neoplasms that is actively recruiting participants, run by john eisenbrey. The registered enrollment target is 266 participants, below the 445-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06261814, a Phase 2 study of Liver Neoplasms, is actively recruiting participants, sponsored by john eisenbrey.

RECRUITING
Registry status
Phase 2
Development phase
266 participants
Enrollment target
1
Study location

Study Summary

This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering Lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods.

Conditions Studied

Liver Neoplasms

Interventions

  • OTHER Medical Chart Review
  • PROCEDURE Contrast-Enhanced Ultrasound
  • DRUG Sulfur Hexafluoride Lipid Microspheres
  • PROCEDURE Transarterial Chemoembolization

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2024-08-07
Est. Completion 2028-01-01
Phase Phase 2

Sponsor

john eisenbrey

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06261814

The ClinicalTrials.gov registry entry for NCT06261814 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 266 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 14 other Liver Neoplasms trials with a reported enrollment target (40% lower). The listed sponsor is john eisenbrey, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Liver Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Medical Chart Review is the first listed.

NCT06261814 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06261814 about?

NCT06261814 is a clinical study titled "Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors". This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent...

What is the current status of trial NCT06261814?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 266 participants. The study started on 2024-08-07. Estimated completion is 2028-01-01.

What conditions does trial NCT06261814 study?

This clinical trial studies the following conditions: Liver Neoplasms.

What interventions are being tested in trial NCT06261814?

The interventions under investigation include: Medical Chart Review (OTHER), Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG), Transarterial Chemoembolization (PROCEDURE).

Who is sponsoring clinical trial NCT06261814?

This trial is sponsored by john eisenbrey, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06261814 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Liver Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Liver Neoplasms

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.